home / stock / alpmy / alpmy news

ALPMY News and Press, Astellas Pharma Inc. ADR From 12/20/18

Stock Information
Company Name: Astellas Pharma Inc. ADR
Stock Symbol: ALPMY
Market: OTC
Menu
ALPMY ALPMY Quote ALPMY Short ALPMY News ALPMY Articles ALPMY Message Board
Get ALPMY Alerts

News, Short Squeeze, Breakout and More Instantly...
ALPMY - Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer

TOKYO and NEW YORK , Dec. 20, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES trial evaluating XTANDI ® (enzalutamide) plus androgen deprivation therap...
ALPMY - Astellas Acquires Potenza Therapeutics

TOKYO and NORTHBROOK, Ill. , Dec. 14, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced that it exercised, and closed on its exclusive option to acquire Potenza Therapeutics, Inc. ("Potenza") on ...

ALPMY - Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

TOKYO , Dec. 10, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") today announced that XOSPATA ® (generic name: gilteritinib) is now available for prescription in the United States for the treatment of adult patients...

ALPMY - Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

TOKYO , Dec. 3, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") today announced updated results from a Phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in patients newly diagnosed w...
ALPMY - Cancer Research Highlight: Astellas Takes Us Into A New Generation Of Therapy For AML

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. If you've followed my news cov...

ALPMY - XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

TOKYO , Nov. 28, 2018 /PRNewswire/ --   Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") today announced that the U.S. Food and Drug Administration (FDA) approved XOSPATA ® (generic name: gilteritinib) for the treatment of adult patients w...

ALPMY - Cancer Research Highlight: AbbVie And Pfizer Blitz Acute Myeloid Leukemia

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Until very recently, patients ...
ALPMY - Astellas Global Health Foundation Launches

TOKYO and NORTHBROOK, Ill. , Nov. 20, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced the launch of the Astellas Global Health Foundation (AGHF), a new international philanthropic organization dedicated to ...

ALPMY - Astellas to Present New Data on Gilteritinib in Multiple Populations of FLT3 Mutation-Positive Acute Myeloid Leukemia (AML) Patients at the 2018 American Society of Hematology (ASH) Annual Meeting

TOKYO , Nov. 19, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Kenji Yasukawa , Ph.D. "Astellas") today announced it will present new data in Acute Myeloid Leukemia (AML) research at the 60th American Society of Hematology (ASH) Annual Meeting, taking place D...

ALPMY - Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

TOKYO and CHERTSEY, England , Sept. 24, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") announced today that The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a posit...
Previous 10 Next 10